PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

Pfizer paid $11.6bn to buy Biohaven, largely on the financial performance of Nurtec ODT. The drug went on to generate global sales of $928m in sales in 2023.

Prior to Pfizer's acquisition of the company, Biohaven knowingly caused the submission of false claims to Medicare and other federal healthcare programs by paying providers to induce them to write ...

The settlement resolves allegations that Biohaven paid improper remuneration, including speaker honoraria and high-end restaurant meals, to physicians and other healthcare professionals to promote ...

Michigan will receive $155,930.53 in the wake of a Pfizer, Inc subsidy agreeing to pay $59.7 million --plus interest-- to resolve kickback allegations Monday.

Nurtec ODT, also known as Rimegepant, was approved for treating acute migraine in February 2020 and its approval was extended to preventing episodic migraine in June 2021.

Pfizer (PFE) has agreed to pay nearly $60M to resolve allegations that its Biohaven unit paid kickbacks to induce prescriptions for its migraine drug Nurtec ODT. Read more here.

Pfizer agreed to pay nearly $60 million to resolve allegations that its Biohaven Pharmaceuticals unit paid kickbacks to entice physicians to prescribe a migraine treatment. The alleged violations ...

Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including further cost cuts, as he seeks to fend off allegations of mismanagement ...

In October 2022, Pfizer completed the acquisition of Biohaven Pharmaceutical Holding Co., the maker of Nurtec ODT, from Biohaven Pharmaceuticals Inc. for about $11.6 billion.